+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Gaucher Disease Type I Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767444
  • Report
  • 69 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Cinven Ltd
  • ISU Chemical Co. Ltd.
  • Johnson & Johnson
  • Sanofi
  • Shire Plc
  • MORE
The global clinical trial report- “2019 Gaucher Disease Type I Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Gaucher Disease Type I. It presents in-depth analysis of Gaucher Disease Type I clinical trials across markets and companies. The research work is for providing complete understanding into trends in Gaucher Disease Type I.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Gaucher Disease Type I clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Gaucher Disease Type I

The research work is prepared through extensive and continuous research on Gaucher Disease Type I trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Gaucher Disease Type I patients are identified
  • The report includes panorama of Gaucher Disease Type I clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Gaucher Disease Type I clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Cinven Ltd
  • ISU Chemical Co. Ltd.
  • Johnson & Johnson
  • Sanofi
  • Shire Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Gaucher Disease Type I Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Gaucher Disease Type I Clinical Trials by Region
2.2.2 Average Enrollment of Gaucher Disease Type I Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Gaucher Disease Type I Treatment, 2019

3. Region wise Gaucher Disease Type I Clinical Trials
3.1 Asia Pacific Gaucher Disease Type I Clinical Trials by Country
3.2 Europe Gaucher Disease Type I Clinical Trials by Country
3.3 North America Gaucher Disease Type I Clinical Trials by Country
3.4 Middle East and Africa Gaucher Disease Type I Clinical Trials by Country
3.5 South and Central America Gaucher Disease Type I Clinical Trials by Country

4. Gaucher Disease Type I Clinical Trial Trends
4.1 Start Year wise Gaucher Disease Type I Clinical Trials
4.2 Phase wise Gaucher Disease Type I Clinical Trials
4.3 Trial Status wise Gaucher Disease Type I Clinical Trials
4.4 Trial Type wise Gaucher Disease Type I Clinical Trials

5. Gaucher Disease Type I Average Enrollment Trends
5.1 Average Enrollment in Gaucher Disease Type I Trials by Year
5.2 Average Enrollment in Gaucher Disease Type I Trials by Phase
5.3 Average Enrollment in Gaucher Disease Type I Trials by Status
5.4 Average Enrollment in Gaucher Disease Type I Trials by Type of Trial

6. Companies Participating in Gaucher Disease Type I Clinical Trials
6.1 Gaucher Disease Type I Trials by Sponsor Type
6.2 Gaucher Disease Type I Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Gaucher Disease Type I Trials- Phase 1
7.2 Gaucher Disease Type I Trials- Phase 2
7.3 Gaucher Disease Type I Trials- Phase 3
7.4 Gaucher Disease Type I Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Gaucher Disease Type I Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Figure 5: Europe - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Figure 7: North America - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Figure 9: Gaucher Disease Type I Clinical Trials by Phase
Figure 10: Gaucher Disease Type I Clinical Trials by Trial Status
Figure 11: Gaucher Disease Type I Clinical Trials by Type
Figure 12: Gaucher Disease Type I Clinical Trials by Sponsor Type
Figure 13: Gaucher Disease Type I Clinical Trials by Leading Sponsors
Figure 14: Gaucher Disease Type I Average Enrollment by Phase
Figure 15: Gaucher Disease Type I Average Enrollment by Trial Status
Figure 16: Gaucher Disease Type I Average Enrollment by Type
Figure 17: Gaucher Disease Type I- Average Enrolment by Type of Sponsors
Figure 18: Gaucher Disease Type I- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Gaucher Disease Type I Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Table 5: Europe - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Table 7: North America - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Gaucher Disease Type I Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Gaucher Disease Type I Average Enrollment by Phase
Table 15: Gaucher Disease Type I Average Enrollment by Trial Status
Table 16: Gaucher Disease Type I Average Enrollment by Type
Table 17: Gaucher Disease Type I- Average Enrolment by Type of Sponsors
Table 18: Gaucher Disease Type I- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Accutest Research Laboratories India Pvt Ltd
  • Amicus Therapeutics Inc
  • Bluefish Pharmaceuticals AB
  • Cinven Ltd
  • DiagnoSearch Life Sciences Pvt Ltd
  • Edenbridge Pharmaceuticals LLC
  • ISU Chemical Co. Ltd.
  • Johnson & Johnson
  • Sanofi
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll